On August 20, XTALPI rose 9.96% in regular trading, trading at HKD 7.925, with turnover of HKD 53.05 million. The stock rebounded sharply following the release of interim results the previous day.

While headline figures showed a swing to a net loss of RMB 251.9 million from a profit of RMB 82.8 million a year earlier, with total revenue declining 23.9% to RMB 393.6 million, the market focused on the underlying growth trajectory. The revenue decline was primarily due to a high comparison base created by a one-time $51 million pipeline licensing upfront payment recognized in the prior-year period. Excluding this factor, core business revenue surged 73.8% year-over-year, with AI4S smart solutions growing 136.4%.

Additionally, the company disclosed that it has secured a strategic AI drug discovery collaboration with a leading international biopharma company worth a potential total of over $400 million. R&D spending rose 66% to RMB 368 million as the company continues investing in autonomous laboratories and agentic systems. The AI pharma sector traded broadly higher, with peers GENSCRIPT BIO up 12.33% and INSILICO up 8.47%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)